{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:21:16Z","timestamp":1790526076558,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T00:00:00Z","timestamp":1317772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Washington State Life Sciences Discovery Fund","award":["LSDF 08-012374880"],"award-info":[{"award-number":["LSDF 08-012374880"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Prostate\u2010specific membrane antigen (PSMA) remains an active target for imaging and therapeutic applications for prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      In the present study, an irreversible phosphoramidate inhibitor, CTT\u201054 (IC\n                      <jats:sub>50<\/jats:sub>\n                      \u2009=\u200914\u2009nM), has been modified to deliver\n                      <jats:sup>99m<\/jats:sup>\n                      Tc\u2010(CO)\n                      <jats:sub>3<\/jats:sub>\n                      \u2010DTPA as a SPECT imaging payload to PSMA+ cells in vivo and in vitro. Percent uptake, competitive binding, and internalization will evaluate the imaging agent in vitro. Preliminary biodistribution and imaging will be utilized for in vivo evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      In vitro studies demonstrate that the radiotracer\n                      <jats:sup>99m<\/jats:sup>\n                      Tc\u2010(CO)\n                      <jats:sub>3<\/jats:sub>\n                      \u2010DTPA\u2010CTT\u201054 exhibits increasing cellular uptake in the PSMA+ LNCaP cells over time. More importantly, it was found that\n                      <jats:sup>99m<\/jats:sup>\n                      Tc\u2010(CO)\n                      <jats:sub>3<\/jats:sub>\n                      \u2010DTPA\u2010CTT\u201054 is rapidly internalized into LNCaP cells, presumably through the PSMA enzyme\u2010inhibitor complex. In a pilot biodistribution study, increasing accumulation of the radiotracer in LNCaP xenografts was observed from 2 to 4\u2009hr and significant clearance from non\u2010target tissues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      While DTPA may not represent the ideal chelate structure for\n                      <jats:sup>99m<\/jats:sup>\n                      Tc(CO)\n                      <jats:sub>3<\/jats:sub>\n                      , the data provides proof\u2010of\u2010concept support for the development of a next\u2010generation phosphoramidate\u2010based PSMA inhibitor\u2010conjugates for use as SPECT imaging agents. Prostate 72:904\u2013912, 2012. \u00a9 2011 Wiley Periodicals, Inc.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.21493","type":"journal-article","created":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T12:41:53Z","timestamp":1317818513000},"page":"904-912","source":"Crossref","is-referenced-by-count":41,"title":["A phosphoramidate\u2010based prostate\u2010specific membrane antigen\u2010targeted SPECT agent"],"prefix":"10.1002","volume":"72","author":[{"given":"Jessie R.","family":"Nedrow\u2010Byers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Jabbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cayla","family":"Jewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanushree","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Benny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford E.","family":"Berkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20288"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003350010240"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.11.012"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2006.07.004"},{"issue":"1","key":"e_1_2_6_6_2","first-page":"27","article-title":"Division of Radiation Oncology RAoSMGICUSA. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer","volume":"7","author":"Rosenthal SA","year":"2001","journal-title":"Tech Urol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.160"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2005.12.015"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac050312q"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2690"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt994"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2005.06.015"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.2310\/7290.2005.05163"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8097"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1162\/153535002320162750"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.03.043"},{"issue":"4","key":"e_1_2_6_17_2","first-page":"610","article-title":"Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate\u2010specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor","volume":"44","author":"Smith\u2010Jones PM","year":"2003","journal-title":"J Nucl Med"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2007.07.010"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v21.i1-3.160"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2741\/salit"},{"issue":"20","key":"e_1_2_6_21_2","first-page":"5807","article-title":"Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate\u2010specific membrane antigen","volume":"62","author":"Lu J","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10117"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.064287"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8043(02)00192-6"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm800111u"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm801055h"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.09.026"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20753"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi801883v"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.066589"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2006.05.008"},{"issue":"6","key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1016\/S0021-9258(18)94074-3","article-title":"Ligand\u2010induced desensitization of 125I\u2010epidermal growth factor internalization","volume":"264","author":"Kuppuswamy D","year":"1989","journal-title":"J Biol Chem"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc800058k"},{"issue":"9","key":"e_1_2_6_34_2","first-page":"1445","article-title":"Prostate\u2010specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells","volume":"2","author":"Pinto JT","year":"1996","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200108112"},{"key":"e_1_2_6_36_2","first-page":"125","volume-title":"Testing for reversibility. Evaluation of enzyme inhibitors in drug discovery: A guide for Medicinal Chemists and Pharmacologists","author":"Copeland RA","year":"2005"},{"issue":"18","key":"e_1_2_6_37_2","first-page":"4055","article-title":"Constitutive and antibody\u2010induced internalization of prostate\u2010specific membrane antigen","volume":"58","author":"Liu H","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910620511"},{"issue":"7","key":"e_1_2_6_39_2","first-page":"1807","article-title":"Expression of the prostate\u2010specific membrane antigen","volume":"54","author":"Israeli RS","year":"1994","journal-title":"Cancer Res"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.21493","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.21493","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.21493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T10:36:42Z","timestamp":1700563002000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.21493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,5]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1002\/pros.21493"],"URL":"https:\/\/doi.org\/10.1002\/pros.21493","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,5]]}}}